Recombinant SARS-CoV-2 Spike-S1 (HEK)

Name: Recombinant SARS-CoV-2 Spike-S1 (HEK)
Availability: InStock

Recombinant SARS-CoV-2 Spike-S1 (HEK)

The native SARS-CoV-2 spike glycoprotein (S) mediates the entry of the virus into target cells via its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor, thereby initiating the infection. It forms a homotrimeric structure on the surface of the SARS-CoV-2 virus and represents the major target for diagnostic and therapeutic agents. The ectodomain of the S glycoprotein comprises the N-terminal S1 subunit, including the receptor binding domain, and the C-terminal S2 subunit.

The recombinant SARS-CoV-2 Spike-S1 (HEK) covers the S1 domain of the viral surface protein including amino

Product data and images for Recombinant SARS-CoV-2 Spike-S1 (HEK)

Figures

Figure 1

**Bead-based immunoassay for detection of patient-derived SARS-CoV-2 antibodies**
. Schematic overview illustrating how our biotinylated antigens can be applied to detect patient-derived SARS-CoV-2 antibodies

Figure 1

Bead-based immunoassay for detection of patient-derived SARS-CoV-2 antibodies

. Schematic overview illustrating how our biotinylated antigens can be applied to detect patient-derived SARS-CoV-2 antibodies

Figure 2

**Results of the bead-based immunoassay using biotinylated Recombinant SARS-CoV-2 Spike-S1 (HEK).**
The amount of captured SARS-CoV-2 antibodies was quantified at different plasma dilutions. Results for plasma from a COVID-19+ patient (circle) or a healthy donor (square) are shown.

Figure 2

Results of the bead-based immunoassay using biotinylated Recombinant SARS-CoV-2 Spike-S1 (HEK).

The amount of captured SARS-CoV-2 antibodies was quantified at different plasma dilutions. Results for plasma from a COVID-19+ patient (circle) or a healthy donor (square) are shown.

Figure 3

**SDS-PAGE of biotinylated Recombinant SARS-CoV-2 Spike S1 (HEK)**
under reduced (R) and non-reduced (NR) conditions.

Figure 3

SDS-PAGE of biotinylated Recombinant SARS-CoV-2 Spike S1 (HEK)

under reduced (R) and non-reduced (NR) conditions.

Specifications for Recombinant SARS-CoV-2 Spike-S1 (HEK)

Overview

The native SARS-CoV-2 spike glycoprotein (S) mediates the entry of the virus into target cells via its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor, thereby initiating the infection. It forms a homotrimeric structure on the surface of the SARS-CoV-2 virus and represents the major target for diagnostic and therapeutic agents. The ectodomain of the S glycoprotein comprises the N-terminal S1 subunit, including the receptor binding domain, and the C-terminal S2 subunit.

The recombinant SARS-CoV-2 Spike-S1 (HEK) covers the S1 domain of the viral surface protein including amino acids V16 to P681 of the native S glycoprotein. The protein is extended at its C-terminus with a His-tag and an AviTag. The recombinant SARS-CoV-2 Spike-S1 (HEK)-Biotin is specifically biotinylated at a single site, preserving full functionality of the protein.

Resources for Recombinant SARS-CoV-2 Spike-S1 (HEK)

Documents and Protocols

Scientific posters

Detection of Humoral and Cellular Responses to SARS-CoV-2 in COVID-19 Convalescents

Application protocol

Bead-based immunoassay for detection of patient-derived SARS-CoV-2 antibodies

Data and images